Innovative Nanoformulations for Intranasal Therapy in Neurodegenerative Disease Management

Neurodegenerative disorders pose a significant global health challenge, driving the need for innovative therapeutic strategies to improve drug delivery efficacy and patient outcomes. Nose-to-brain delivery, facilitated by advanced nanoformulations, offers a promising solution to overcome the blood-brain barrier (BBB) and optimize drug targeting for central nervous system (CNS) treatments. This review explores recent advancements in nanoformulation technologies tailored for nose-to-brain delivery, particularly in insomnia and other CNS disorders. Key topics include nanocarrier design strategies, pharmacokinetics, therapeutic efficacy, and clinical implications. Nanoformulations enhance drug bioavailability, minimize systemic side effects, and improve patient compliance, marking a transformative shift in neurodegenerative disorder treatments. The olfactory region and hypothalamic microvasculature bypass the BBB, enabling direct and efficient drug delivery to the brain. This is particularly critical for proteins and peptides, which often exhibit short plasma half-lives and limited natural brain interaction. Emerging formulation strategies, such as surface modifications, incorporation of cutting-edge materials, and particle property optimization, address challenges like drug stability, release kinetics, and targeting specificity. These approaches aim to maximize therapeutic absorption while minimizing nanoformulation-induced toxicity in the nasal mucosa. Such advancements reduce side effects, improving the safety and efficacy of nose-to-brain drug delivery systems. This review serves as an invaluable resource for researchers, clinicians, and pharmaceutical professionals focused on developing innovative, safe, and efficient treatments for neurodegenerative diseases, potentially revolutionizing CNS therapy through nanotechnology-driven approaches.